Bionomics Limited (BNO)

Welcome to InvestSMART

You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:

Sign Up Today Ľ it's FREE! Already a member? Login now!

General Information
Company Name: Bionomics Limited
Stock Code: BNO
GICS Sub-Industry: Biotechnology
Market Cap ($M): 240
Equiv. Shares (M): 417

Current Price Data+
Current Price Open High Low Last Close Volume Price Movement
$ 0.575 $ 0.580 $ 0.580 $ 0.570 $ 0.575 249,458 0%

Current Broker Consensus Recommendation more
Recommendation: Buy (2)
Recommendation Date: 16th Sep 2014
Brokers Surveyed: 1

Company Overview

Business Description:
Bionomics Limited (BNO) is an Australian biotechnology company focused on the discovery and development of cancer, central nervous system disorders such as anxiety, depression and Alzheimer's Disease. BNO partners with pharmaceutical companies to get the drugs through the later stages of development and into the market.

Strategy Analysis:
BNO seeks to develop compounds to successful proof of concept in human clinical trials. The company is open to partnership at all stages of development. Additionally, BNO is open to in-licensing proposals that are in alignment with the company's overall therapeutic focus in cancer, inflammatory disorders and CNS diseases.

Financial Summary
Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016  F 31.1 7.4 32.1 7.8 -- 0.0 --
2015  F 23.8 5.6 600.0 10.2 -- 0.0 --
2014  A 3.2 0.8 -- 79.8 0.0 0.0 --
Source: Aspect actuals / Thomson IBES estimates

Peer Comparison
EPS Growth (%) P/E (%) Dividend Yield (%)
Company Mkt Cap 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F 2014 A 2015 F 2016 F
Bionomics (BNO) $240 M -- 6.3247 0.3032 74.6753 10.1950 7.8231 0.00 0.00 0.00
CSL (CSL) $34,458 M 0.0899 0.1803 0.1256 25.4139 21.5315 19.1284 1.65 1.96 2.16
Mesoblast (MSB) $1,582 M -- -- -- -- -- -- 0.00 0.00 0.00
Starpharma (SPL) $202 M -- -- -0.9512 -- 8.6691 177.5000 0.00 0.00 0.00
Sirtex Medical (SRX) $1,237 M 0.2906 0.5104 0.3721 53.0266 35.1074 25.5871 0.00 0.83 1.37

Market Comparison
Earnings P/E Ratio P/B Ratio P/E Growth P/S Ratio
BNO 0.91 31.5 5.35 0.15 8.89
Market 1.13 14.0 0.99 1.03 3.64
Sector 0.69 22.2 3.19 1.36 8.75

Name Position Start Date
Dr Deborah Rathjen Chief Executive Officer,Managing Director 18 May 2000
Mr Graeme Kaufman Non-Executive Director 18 September 2012
Mr Trevor Tappenden Non-Executive Director 18 September 2006
Errol De Souza Non-Executive Director 28 February 2008
Dr Jonathan Lim Non-Executive Director 14 September 2012

Name Position
Melanie Young Chief Financial Officer,Company Secretary
Jose Iglesias Chief Medical Officer
Emile Andriambeloson Head of Research, Neurofit
Sue O'Connor Senior Director, CNS Research & Development
Forrest Fuller Vice President Business Development
Jeremy Simpson Vice President Clinical Development
Andrew Harvey Vice President Drug Discovery
Gabriel Kremmidiotis Vice President Research and Development
Christopher Reyes Vice President Research and Development Biologics
Peter Chu Vice President US Operations & Cancer Biology

Substantial Shareholders
Holding Name
24,000,000 (5.84%) Ausbil Dexia Limited
34,624,622 (8.42%) Link Traders (Aust) Pty Limited
21,642,425 (5.26%) Australian National University
24,241,071 (5.90%) John Leaver

Calendar of Events
Date Event
18 August 2015 Report (Prelim)
17 February 2015 Report (Interim)
17 October 2014 Report (Annual)
© 2011 Morningstar, Inc. All rights reserved. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for use or distribution of any of this information. To the extent that any of the content above constitutes advice, it is general advice that has been prepared by Morningstar Australasia Pty Ltd ABN: 95 090 665 544, AFSL: 240892 (a subsidiary of Morningstar, Inc.), without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain financial, legal and taxation advice before making any financial investment decision. If applicable investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). DISCLOSURE: Employees may have an interest in the securities discussed in this report. Please refer to our Financial Services Guide (FSG) for more information at


Trade Shares Online from $19.95^
Free Guides

The SMH Guide to Investing in Art

An educational booklet with useful, practical tips to help you make better-informed decisions about investing in art.

More details...


Billionaires bankroll Ten's new direction Media Network sees digital future

The Age 19/12/2013 | Ten Network's programming ambitions will be funded by a $200 million loan guaranteed by three of its billionaire owners, as the free-to-air broadcaster declared digital was the future and pointed to early signs that its switch to an older market demographic was working.

Elders alleges $24m fraud in live cattle division

The Age 19/12/2013 | Troubled rural services group Elders is threatening to call in the police over an alleged $24 million fraud by a "handful of individuals" in its live cattle exports division.

Bega Cheese holds back in three-way bidding war for WCB

The Age 19/12/2013 | Bega Cheese began the battle for Warrnambool Cheese & Butter but three months on it appears to be the first casualty of the bidding war.

Aussie hampers transition

The Age 19/12/2013 | A persistently high Australian dollar is thwarting the Reserve Bank's efforts to ease the transition of the economy away from mining.

RBA keeps its focus on lower dollar

The Age 19/12/2013 | The Reserve Bank is keeping the door open to further interest rate cuts, but believes the "significant amount" of monetary policy easing over the past two years is already stimulating growth.

Pact's struggles weigh down Orora

The Age 19/12/2013 | The underwhelming sharemarket debut of packaging company Pact Group Holdings has weighed on the demerger of Amcor and its $2 billion Australasian packaging and distribution business Orora.


Sponsored Links